B-type natriuretic peptide: Distribution in the general population and the association with major cardiovascular and coronary events - The Heinz Nixdorf Recall Study

Clinical Research in Cardiology

Volumn 103, Issue 2, 2014, Pages 125-132

  Kara, Kaffer ^a,d   Mahabadi, Amir A ^a   Geisel, Marie H ^a   Lehmann, Nils ^a   Kälsch, Hagen ^a   Bauer, Marcus ^a   Neumann, Till ^a   Dragano, Nico ^b   Moebus, Susanne ^a   Möhlenkamp, Stefan ^c   Jöckel, Karl Heinz ^a   Erbel, Raimund ^a  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

^c Krankenhaus Bethanien   (Germany)

^d ST JOSEF HOSPITAL   (Germany)

Author keywords

Heinz Nixdorf Recall Study; Natriuretic peptides; Prevention; Risk factors

Indexed keywords

ADULT; AGE DISTRIBUTION; AGE FACTORS; AGED; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; FEMALE; GERMANY; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; NATRIURETIC PEPTIDE, BRAIN; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; REFERENCE VALUES; SEX DISTRIBUTION; SEX FACTORS;

EID: 84893871470     PISSN: 18610684     EISSN: 18610692     Source Type: Journal    
DOI: 10.1007/s00392-013-0628-4     Document Type: Article

References (32)

1. Maisel AS, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, Duc P, Omland T, Storrow AB, Abraham WT, Wu AH, Clopton P, Steg PG, Westheim A, Knudsen CW, Perez A, Kazanegra R, Herrmann HC, McCullough PA, Breathing Not Properly Multinational Study Investigators (2002) Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 347:161-167 (Pubitemid 34764819)
2. Yasue H, Yoshimura M, Sumida H, Kikuta K, Kugiyama K, Jougasaki M, Ogawa H, Okumura K, Mukoyama M, Nakao K (1994) Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation 90:195-203 (Pubitemid 24203680)
3. Januzzi JL Jr, Camargo CA, Anwaruddin S, Baggish AL, Chen AA, Krauser DG, Tung R, Cameron R, Nagurney JT, Chae CU, Lloyd-Jones DM, Brown DF, Foran-Melanson S, Sluss PM, Lee-Lewandrowski E, Lewandrowski KB (2005) The N-terminal pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol 95:948-954 (Pubitemid 40487743)
4. Böhm M, Voors AA, Ketelslegers JM, Schirmer SH, Turgonyi E, Bramlage P, Zannad F (2011) Biomarkers: optimizing treatment guidance in heart failure. Clin Res Cardiol 100:973-981
5. Goetze JP, Christoffersen C, Perko M, Arendrup H, Rehfeld JF, Kastrup J, Nielsen LB (2003) Increased cardiac BNP expression associated with myocardial ischemia. FASEB J 17:1105-1107
6. Hama N, Itoh H, Shirakami G, Nakagawa O, Suga S, Ogawa Y, Masuda I, Nakanishi K, Yoshimasa T, Hashimoto Y, Yamaguchi M, Hori R, Yasue H, Nakao K (1995) Rapid ventricular induction of brain natriuretic peptide gene expression in experimental acute myocardial infarction. Circulation 92:1558-1564
7. Struthers A, Lang C (2007) The potential to improve primary prevention in the future by using BNP/N-BNP as an indicator of silent 'pancardiac' target organ damage: BNP/N-BNP could become for the heart what microalbuminuria is for the kidney. Eur Heart J 28:1678-1682 (Pubitemid 47227107)
8. Nadir MA, Rekhraj S, Wei L, Lim TK, Davidson J, MacDonald TM, Lang CC, Dow E, Struthers AD (2012) Improving the primary prevention of cardiovascular events by using biomarkers to identify individuals with silent heart disease. J Am Coll Cardiol 60:960-968
9. Wang TJ, Larson MG, Levy D, Benjamin EJ, Leip EP, Omland T, Wolf PA, Vasan RS (2004) Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med 350:655-663 (Pubitemid 38364624)
10. Nakamura M, Tanaka F, Takahashi T, Makita S, Ishisone T, Onodera M, Ishibashi Y, Itai K, Onoda T, Ohsawa M, Tanno K, Sakata K, Shinichi O, Ogasawara K, Ogawa A, Kuribayashi T, Okayama A (2011) Sex-specific threshold levels of plasma B-type natriuretic Peptide for prediction of cardiovascular event risk in a Japanese population initially free of cardiovascular disease. Am J Cardiol 108:1564-1569
11. Di Angelantonio E, Chowdhury R, Sarwar N, Ray KK, Gobin R, Saleheen D, Thompson A, Gudnason V, Sattar N, Danesh J (2009) B-type natriuretic peptides and cardiovascular risk: systematic review and meta-analysis of 40 prospective studies. Circulation 120:2177-2187
12. Linssen GC, Bakker SJ, Voors AA, Gansevoort RT, Hillege HL, de Jong PE, van Veldhuisen DJ, Gans RO, de Zeeuw D (2010) N-terminal pro-B-type natriuretic peptide is an independent predictor of cardiovascular morbidity and mortality in the general population. Eur Heart J 31:120-127
13. Rutten JH, Mattace-Raso FU, Steyerberg EW, Lindemans J, Hofman A, Wieberdink RG, Breteler MM, Witteman JC, van den Meiracker AH (2010) Amino-terminal pro-B-type natriuretic peptide improves cardiovascular and cerebrovascular risk prediction in the population: the Rotterdam study. Hypertension 55:785-791
14. Leistner DM, Klotsche J, Pieper L, Palm S, Stalla GK, Lehnert H, Silber S, März W, Wittchen HU, Zeiher AM (2013) Prognostic value of NT-pro-BNP and hs-CRP for risk stratification in primary care: results from the population-based DETECT study. Clin Res Cardiol 102:259-268
15. Nakamura M, Tanaka F, Onoda T, Takahashi T, Sakuma M, Kawamura K, Tanno K, Ohsawa M, Itai K, Sakata K, Makita S, Iwate KENCO Study Groups (2010) Gender-specific risk stratification with plasma B-type natriuretic peptide for future onset of congestive heart failure and mortality in the Japanese general population. Int J Cardiol 143:124-129
16. Raymond I, Groenning BA, Hildebrandt PR, Nilsson JC, Baumann M, Trawinski J, Pedersen F (2003) The influence of age, sex and other variables on the plasma level of N-terminal pro brain natriuretic peptide in a large sample of the general population. Heart 89:745-751 (Pubitemid 36760633)
17. Erbel R, Möhlenkamp S, Moebus S, Schmermund A, Lehmann N, Stang A, Dragano N, Grönemeyer D, Seibel R, Kälsch H, Bröcker-Preuss M, Mann K, Siegrist J, Jöckel KH, Heinz Nixdorf Recall Study Investigative Group (2010) Coronary risk stratification, discrimination, and reclassification improvement based on quantification of subclinical coronary atherosclerosis: The Heinz Nixdorf Recall study. J Am Coll Cardiol 56:1397-1406
18. Schmermund A, Möhlenkamp S, Stang A, Grönemeyer D, Seibel R, Hirche H, Mann K, Siffert W, Lauterbach K, Siegrist J, Jöckel KH, Erbel R (2002) Assessment of clinically silent atherosclerotic disease and established and novel risk factors for predicting myocardial infarction and cardiac death in healthy middle-aged subjects: rationale and design of the Heinz Nixdorf Recall Study. Risk Factors, Evaluation of Coronary Calcium and Lifestyle. Am Heart J 144:212-218 (Pubitemid 34879641)
19. Möhlenkamp S, Lehmann N, Moebus S, Schmermund A, Dragano N, Stang A, Siegrist J, Mann K, Jöckel KH, Erbel R, Heinz Nixdorf Recall Study Investigators (2011) Quantification of coronary atherosclerosis and inflammation to predict coronary events and all-cause mortality. J Am Coll Cardiol 57:1455-1464
20. Schmermund A, Möhlenkamp S, Berenbein S, Pump H, Moebus S, Roggenbuck U, Stang A, Seibel R, Grönemeyer D, Jöckel KH, Erbel R (2006) Population-based assessment of subclinical coronary atherosclerosis using electron-beam computed tomography. Atherosclerosis 185:177-182 (Pubitemid 43117566)
21. Stang A, Moebus S, Dragano N, Beck EM, Möhlenkamp S, Schmermund A, Siegrist J, Erbel R, Jöckel KH, Heinz Nixdorf Recall Study Investigation Group (2005) Baseline recruitment and analyses of nonresponse of the Heinz Nixdorf Recall Study: identifiability of phone numbers as the major determinant of response. Eur J Epidemiol 20:489-496 (Pubitemid 40933925)
22. Schmermund A, Lehmann N, Bielak LF, Yu P, Sheedy PF 2nd, Cassidy-Bushrow AE, Turner ST, Moebus S, Möhlenkamp S, Stang A, Mann K, Jöckel KH, Erbel R, Peyser PA (2007) Comparison of subclinical coronary atherosclerosis and risk factors in unselected populations in Germany and US-America. Atherosclerosis 195:207-216 (Pubitemid 47566387)
23. Jöckel KH, Lehmann N, Jaeger BR, Moebus S, Möhlenkamp S, Schmermund A, Dragano N, Stang A, Grönemeyer D, Seibel R, Mann K, Volbracht L, Siegrist J, Erbel R (2009) Smoking cessation and subclinical atherosclerosis-results from the Heinz Nixdorf Recall Study. Atherosclerosis 203:221-227
24. Moebus S, Stang A, Möhlenkamp S, Dragano N, Schmermund A, Slomiany U, Hoffmann B, Bauer M, Broecker-Preuss M, Mann K, Siegrist J, Erbel R, Jöckel KH, Heinz Nixdorf Recall Study Group (2009) Association of impaired fasting glucose and coronary artery calcification as a marker of subclinical atherosclerosis in a population-based cohort-results of the Heinz Nixdorf Recall Study. Diabetologia 52:81-89
25. Agatston AS, Janowitz WR, Hildner FJ, Zusmer NR, Viamonte M Jr, Detrano R (1990) Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol 15:827-832 (Pubitemid 20101575)
26. Erbel R, Möhlenkamp S, Lehmann N, Schmermund A, Moebus S, Stang A, Grönemeyer D, Seibel R, Mann K, Volbracht L, Dragano N, Siegrist J, Jöckel KH (2008) Sex related cardiovascular risk stratification based on quantification of atherosclerosis and inflammation. Atherosclerosis 197:662-672 (Pubitemid 351419239)
27. Truong QA, Massaro JM, Rogers IS, Mahabadi AA, Kriegel MF, Fox CS, O'Donnell CJ, Hoffmann U (2011) Reference values for normal pulmonary artery dimensions by noncontrast cardiac computed tomography: the Framingham Heart Study. Circ Cardiovasc Imaging 5:147-154
28. Rogers IS, Massaro JM, Truong QA, Mahabadi AA, Kriegel MF, Fox CS, Thanassoulis G, Isselbacher EM, Hoffmann U, O'Donnell CJ (2013) Distribution, determinants, and normal reference values of thoracic and abdominal aortic diameters by computed tomography (from the Framingham Heart Study). Am J Cardiol 111:1510-1516
29. Thanassoulis G, Massaro JM, Hoffmann U, Mahabadi AA, Vasan RS, O'Donnell CJ, Fox CS (2010) Prevalence, distribution, and risk factor correlates of high pericardial and intrathoracic fat depots in the Framingham heart study. Circ Cardiovasc Imaging 3:559-566
30. Schoenfeld D (1982) Partial residuals for the proportional hazards regression model. Biometrika 69:239-241
31. Lin D, Wei LJ, Ying Z (1993) Checking the cox model with cumulative sums of martingale-based residuals. Biometrika 80:557-572
32. Kara K, Mahabadi AA, Berg MH, Lehmann N, Möhlenkamp S, Kälsch H, Bauer M, Moebus S, Dragano N, Jöckel KH, Neumann T, Erbel R (2013) Predicting Risk of Coronary Events and All-cause Mortality: Role of B-Type Natriuretic Peptide above Traditional Risk Factors and Coronary Artery Calcium Scoring in the General Population - The Heinz Nixdorf Recall Study. Eur J Prev Cardiol [Epub ahead of print]